Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BKK:JSP-R's Price-to-Tangible-Book is ranked better than 68.12% of 1813
companies
in the Consumer Packaged Goods industry
Industry Median: 1.57
vs BKK:JSP-R: 0.97
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
JSP Pharmaceutical Manufacturing (Thailand) PCL Price-to-Tangible-Book Related Terms
JSP Pharmaceutical Manufacturing (Thailand) PCL Price-to-Tangible-Book Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:JSP-R vs KHC, GIS: Price-to-Tangible-Book Comparison
For the Packaged Foods subindustry, JSP Pharmaceutical Manufacturing (Thailand) PCL's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JSP Pharmaceutical Manufacturing (Thailand) PCL Price-to-Tangible-Book vs Consumer Packaged Goods Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) has a Price-to-Tangible-Book of 0.97 as of Aug. 31, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors. According to the industry distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #578 out of 1813 companies in the Consumer Packaged Goods industry, placing it in the top 31.9%.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL's Price-to-Tangible-Book too high?
JSP Pharmaceutical Manufacturing (Thailand) PCL's current Price-to-Tangible-Book is 0.97. The Consumer Packaged Goods industry median Price-to-Tangible-Book is 1.57. JSP Pharmaceutical Manufacturing (Thailand) PCL's value of 0.97 is 38.2% below this industry median. Based on the distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #578 out of 1813 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, JSP Pharmaceutical Manufacturing (Thailand) PCL has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JSP Pharmaceutical Manufacturing (Thailand) PCL's Price-to-Tangible-Book compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #578 out of 1813 companies for Price-to-Tangible-Book. This puts JSP Pharmaceutical Manufacturing (Thailand) PCL in the upper half of its industry. The industry median Price-to-Tangible-Book is 1.57. JSP Pharmaceutical Manufacturing (Thailand) PCL's value of 0.97 is 38.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Consumer Packaged Goods company?
The median Price-to-Tangible-Book among Consumer Packaged Goods companies is 1.57, based on 1,813 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JSP Pharmaceutical Manufacturing (Thailand) PCL's current Price-to-Tangible-Book of 0.97 is 38.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors. For the Consumer Packaged Goods industry, the median Price-to-Tangible-Book is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JSP Pharmaceutical Manufacturing (Thailand) PCL's current Price-to-Tangible-Book is 0.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL stock overvalued right now?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿2.18, compared to a current price of ฿1.75 — trading 19.9% below its estimated fair value. The current Price-to-Tangible-Book is 0.97 and 38.2% below the Consumer Packaged Goods industry median of 1.57. JSP Pharmaceutical Manufacturing (Thailand) PCL's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R), the current Price-to-Tangible-Book is 0.97 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) Overvalued in 2026?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL stock appears to be undervalued.
The current stock price of ฿1.75 is trading 19.9% below its estimated GF Value™ of ฿2.18.
GuruFocus considers JSP Pharmaceutical Manufacturing (Thailand) PCL to be Modestly Undervalued.
Key valuation signals for BKK:JSP-R:
Price-to-Tangible-Book: 0.97
GF Value™: ฿2.18 vs. price of ฿1.75 (19.9% below fair value)
Industry Position: 38.2% below the Consumer Packaged Goods median (#578 of 1813)
No single metric tells the full story. See the BKK:JSP-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JSP Pharmaceutical Manufacturing (Thailand) PCL is engaged in producing modern medicine, traditional medicine, herbal products, dietary supplements, medical supplies, and cleaning alcohol under the client's and the company's own trademarks. Maximum revenue for the company is generated from the sale of dietary supplements. The Group's reportable operating segments are: Manufacture and distribution of products under the company's brand name (Own brands), which generate maximum revenue, Manufacture and distribution of products under customers' brand name (OEM), Manufacture and distribution of hemodialysis solution and related medical supplies; and Service, research and development, and healthcare products training. Geographically, it operates principally in Thailand.
82GF Score
Get the complete analysis for BKK:JSP-R
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:JSP-R has been successfully added to your 
